Cargando…
Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
INTRODUCTION: Renal cell carcinoma has been considered radioresistant. Recently, several studies have reported the efficacy of combination therapy using radiotherapy and immune checkpoint inhibitors. CASE PRESENTATION: In 1999, a 56‐year‐old woman underwent left nephrectomy (clear cell carcinoma, pT...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469856/ https://www.ncbi.nlm.nih.gov/pubmed/32914080 http://dx.doi.org/10.1002/iju5.12195 |
_version_ | 1783578479858548736 |
---|---|
author | Nakajima, Nobuyuki Kano, Tatsuo Oda, Kazuya Uchida, Takato Otaki, Tatsuya Nagao, Kentaro Shimizu, Yuki Kawakami, Masayoshi Kim, Hakushi Nitta, Masahiro Hasegawa, Masanori Kawamura, Yoshiaki Miyajima, Akira |
author_facet | Nakajima, Nobuyuki Kano, Tatsuo Oda, Kazuya Uchida, Takato Otaki, Tatsuya Nagao, Kentaro Shimizu, Yuki Kawakami, Masayoshi Kim, Hakushi Nitta, Masahiro Hasegawa, Masanori Kawamura, Yoshiaki Miyajima, Akira |
author_sort | Nakajima, Nobuyuki |
collection | PubMed |
description | INTRODUCTION: Renal cell carcinoma has been considered radioresistant. Recently, several studies have reported the efficacy of combination therapy using radiotherapy and immune checkpoint inhibitors. CASE PRESENTATION: In 1999, a 56‐year‐old woman underwent left nephrectomy (clear cell carcinoma, pT1bN0M0). Seventeen years postoperatively, recurrence in the left lung hilum was observed. Despite administration of three molecular target drugs, all treatments were terminated due to adverse events. Nivolumab was initiated in December 2016. In August 2017, subcutaneous and lung metastases were observed. Moreover in January 2018, right renal metastasis was noted. After 22 cycles of nivolumab treatment, metastasis in the iliac bone was observed, and the patient was subjected to conventional palliative external beam radiation therapy. Five months after radiotherapy, there was significant reduction in multiple metastases. Here, we reported the case presenting with possible abscopal effect. CONCLUSION: Radiotherapy combined with immune checkpoint inhibitors may induce systemic effects against metastatic renal carcinoma. |
format | Online Article Text |
id | pubmed-7469856 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74698562020-09-09 Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma Nakajima, Nobuyuki Kano, Tatsuo Oda, Kazuya Uchida, Takato Otaki, Tatsuya Nagao, Kentaro Shimizu, Yuki Kawakami, Masayoshi Kim, Hakushi Nitta, Masahiro Hasegawa, Masanori Kawamura, Yoshiaki Miyajima, Akira IJU Case Rep Case Reports INTRODUCTION: Renal cell carcinoma has been considered radioresistant. Recently, several studies have reported the efficacy of combination therapy using radiotherapy and immune checkpoint inhibitors. CASE PRESENTATION: In 1999, a 56‐year‐old woman underwent left nephrectomy (clear cell carcinoma, pT1bN0M0). Seventeen years postoperatively, recurrence in the left lung hilum was observed. Despite administration of three molecular target drugs, all treatments were terminated due to adverse events. Nivolumab was initiated in December 2016. In August 2017, subcutaneous and lung metastases were observed. Moreover in January 2018, right renal metastasis was noted. After 22 cycles of nivolumab treatment, metastasis in the iliac bone was observed, and the patient was subjected to conventional palliative external beam radiation therapy. Five months after radiotherapy, there was significant reduction in multiple metastases. Here, we reported the case presenting with possible abscopal effect. CONCLUSION: Radiotherapy combined with immune checkpoint inhibitors may induce systemic effects against metastatic renal carcinoma. John Wiley and Sons Inc. 2020-07-07 /pmc/articles/PMC7469856/ /pubmed/32914080 http://dx.doi.org/10.1002/iju5.12195 Text en © 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Nakajima, Nobuyuki Kano, Tatsuo Oda, Kazuya Uchida, Takato Otaki, Tatsuya Nagao, Kentaro Shimizu, Yuki Kawakami, Masayoshi Kim, Hakushi Nitta, Masahiro Hasegawa, Masanori Kawamura, Yoshiaki Miyajima, Akira Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma |
title | Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma |
title_full | Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma |
title_fullStr | Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma |
title_full_unstemmed | Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma |
title_short | Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma |
title_sort | possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469856/ https://www.ncbi.nlm.nih.gov/pubmed/32914080 http://dx.doi.org/10.1002/iju5.12195 |
work_keys_str_mv | AT nakajimanobuyuki possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT kanotatsuo possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT odakazuya possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT uchidatakato possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT otakitatsuya possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT nagaokentaro possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT shimizuyuki possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT kawakamimasayoshi possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT kimhakushi possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT nittamasahiro possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT hasegawamasanori possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT kawamurayoshiaki possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma AT miyajimaakira possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma |